Document is current
Any future updates will be listed below
-
Authors
Serizawa, Kentaro
Tanaka, Hirokazu https://orcid.org/0000-0002-7192-525X
Ueda, Takeshi
Fukui, Ayano
Kakutani, Hiroaki
Taniguchi, Takahide
Inoue, Hiroaki
Kumode, Takahiro
Taniguchi, Yasuhiro
Rai, Shinya
Hirase, Chikara
Morita, Yasuyoshi
Espinoza, J. Luis
Tatsumi, Yoichi
Ashida, Takashi
Matsumura, Itaru
- License Information
-
More Information
Article History
Received: 20 September 2021
Revised: 12 November 2021
Accepted: 12 November 2021
First Online: 8 February 2022
Declarations
:
: K.S. received personal fees from ONO PHARMACEUTICAL CO., LTD., Janssen Pharmaceutical K.K, Takeda Pharmaceutical Company Limited, Sanofi, and Bristol-Myers Squibb (Celgene). H.T. received grants from JSPS KAKENHI, ONO PHARMACEUTICAL CO., LTD., and Kyowa Kirin Co., Ltd.; personal fees from Bristol-Myers Squibb (Celgene), Novartis Pharmaceuticals, ONO PHARMACEUTICAL CO., LTD., Janssen Pharmaceutical K.K, Takeda Pharmaceutical Company Limited., Sanofi, Meiji Seika Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Adaptive Biotechnologies. S.R. received personal fees from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Bristol-Myers Squibb (Celgene), Janssen Pharmaceutical K.K, Takeda Pharmaceutical Company Limited., and Amgen BioPharma K.K., and Mundipharma K.K. Y.M. received personal fees from AbbVie GK, NIPPON SHINYAKU CO., LTD., and Alexion Pharmaceuticals, Inc. I.M. received grants from ONO PHARMACEUTICAL CO., LTD., NIPPON SHINYAKU CO., LTD., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Shionogi & Co., Ltd., TEIJIN PHARMA LIMITED., Boehringer Ingelheim, Sanofi, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., MSD K.K, ASAHI KASEI PHARMA CORPORATION, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited., Japan Blood Products Organization, NIHON PHARMACEUTICAL CO., LTD, DAIICHI SANKYO COMPANY, TAIHO PHARMACEUTICAL CO., LTD., Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co.,Ltd., CSL Behring, Mundipharma K.K, AYUMI Pharmaceutical Corporation, Eli Lilly Japan K.K., and Actelion Pharmaceuticals Japan Ltd.,; personal fees from Bristol-Myers Squibb (Celgene), Novartis Pharmaceuticals, ONO PHARMACEUTICAL CO., LTD., Janssen Pharmaceutical K.K, NIPPON SHINYAKU CO.,LTD., Shionogi & Co., Ltd., Astellas Pharma Inc., Takeda Pharmaceutical Company Limited., DAIICHI SANKYO COMPANY, AbbVie GK, and Amgen BioPharma K.K. The remaining authors declare no competing financial interests.
